Headquartered in Oakland, California, The Clorox Company (CLX) is a global manufacturer and marketer of consumer and professional products and is valued at a market cap of $20.2 billion. Clorox provides consumers with a wide array of premium cleaning, health, and wellness products, ranging from household cleaners and disinfectants to personal care essentials.
Companies valued at $10 billion or more are classified as “large-cap” stocks, and Clorox Company exemplifies this with its strong market position and consistent growth in the global consumer goods industry. Clorox stands out due to its trusted brand reputation, broad product portfolio, and focus on innovation. The company caters to diverse consumer needs with high-quality cleaning, health, and wellness products, including household cleaners, disinfectants, and personal care items.
CLX shares are trading 4.6% below their 52-week high of $171.37, which they hit on Dec. 6. The stock has fallen marginally over the past three months, lagging behind the broader Nasdaq Composite ($NASX), which has soared 10.8% over the same time frame.
In the longer term, CLX has surged 20.1% over the past six months, while NASX has gained 14.5%. Over the past year, CLX has soared 15.2%, compared to NASX’s 33.6% rise.
To confirm its bullish trend, CLX has been trading above its 200-day moving average since early August but has come under the 50-day moving average recently.
On Oct. 30, Clorox unveiled its Q1 earnings, which led to its shares to jump more than 3% in the next two trading sessions. The results exceeded expectations, driven by a full recovery in market share, robust product offerings, and stronger performance overall. An improved outlook for gross margin and EPS was further supported by the company’s IGNITE strategy, positioning Clorox for sustained growth in the long term.
Highlighting the contrast in performance, CLX’s competitor, Colgate-Palmolive Company (CL), has underperformed with a 6.7% decline over the past six months.
Given CLX’s mixed price performance over the past year, analysts are concerned about CLX’s prospects. The stock has a consensus rating of “Hold” from 20 analysts in coverage. The stock currently trades above its mean price target of $161.17.
On the date of publication,
Kritika Sarmah
did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy
here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
